[HTML][HTML] Mycophenolate mofetil for scleroderma-related interstitial lung disease: a real world experience
M Baqir, A Makol, TG Osborn, BJ Bartholmai, JH Ryu - PLoS One, 2017 - journals.plos.org
Background and objective Interstitial lung disease (ILD) remains the number one cause of
mortality in scleroderma (SSc). Our goal was to determine the effectiveness of …
mortality in scleroderma (SSc). Our goal was to determine the effectiveness of …
[PDF][PDF] Mycophenolate mofetil for scleroderma-related interstitial lung disease: A real world experience
M Baqir, A Makol, TG Osborn, BJ Bartholmai… - PLoS …, 2017 - pdfs.semanticscholar.org
Methods A retrospective, computer-assisted search was performed to identify patients with
SSc-ILD treated with MMF from 1997 through 2014. We used a novel software tool …
SSc-ILD treated with MMF from 1997 through 2014. We used a novel software tool …
Mycophenolate mofetil for scleroderma-related interstitial lung disease: A real world experience.
M Baqir, A Makol, TG Osborn, BJ Bartholmai… - PLoS …, 2017 - search.ebscohost.com
Background and objective: Interstitial lung disease (ILD) remains the number one cause of
mortality in scleroderma (SSc). Our goal was to determine the effectiveness of …
mortality in scleroderma (SSc). Our goal was to determine the effectiveness of …
[引用][C] Mycophenolate mofetil for scleroderma-related interstitial lung disease: A real world experience
M Baqir, A Makol, TG Osborn, BJ Bartholmai… - PLoS …, 2017 - ui.adsabs.harvard.edu
Mycophenolate mofetil for scleroderma-related interstitial lung disease: A real world
experience - NASA/ADS Now on home page ads icon ads Enable full ADS view NASA/ADS …
experience - NASA/ADS Now on home page ads icon ads Enable full ADS view NASA/ADS …
Mycophenolate mofetil for scleroderma-related interstitial lung disease: A real world experience
M Baqir, A Makol, TG Osborn, BJ Bartholmai, JH Ryu - PLoS ONE, 2017 - go.gale.com
Background and objective Interstitial lung disease (ILD) remains the number one cause of
mortality in scleroderma (SSc). Our goal was to determine the effectiveness of …
mortality in scleroderma (SSc). Our goal was to determine the effectiveness of …
[HTML][HTML] Mycophenolate mofetil for scleroderma-related interstitial lung disease: A real world experience
M Baqir, A Makol, TG Osborn, BJ Bartholmai, JH Ryu - PLoS ONE, 2017 - ncbi.nlm.nih.gov
Methods A retrospective, computer-assisted search was performed to identify patients with
SSc-ILD treated with MMF from 1997 through 2014. We used a novel software tool …
SSc-ILD treated with MMF from 1997 through 2014. We used a novel software tool …
Mycophenolate mofetil for scleroderma-related interstitial lung disease: A real world experience
M Baqir, A Makol, TG Osborn, BJ Bartholmai, JH Ryu - PLOS ONE, 2017 - ideas.repec.org
Background and objective: Interstitial lung disease (ILD) remains the number one cause of
mortality in scleroderma (SSc). Our goal was to determine the effectiveness of …
mortality in scleroderma (SSc). Our goal was to determine the effectiveness of …
Mycophenolate mofetil for scleroderma-related interstitial lung disease: A real world experience
M Baqir, A Makol, TG Osborn, BJ Bartholmai… - PloS one, 2017 - pubmed.ncbi.nlm.nih.gov
Background and objective Interstitial lung disease (ILD) remains the number one cause of
mortality in scleroderma (SSc). Our goal was to determine the effectiveness of …
mortality in scleroderma (SSc). Our goal was to determine the effectiveness of …
Mycophenolate mofetil for sclerodermarelated interstitial lung disease: A real world experience
M Baqir, A Makol, TG Osborn, BJ Bartholmai… - PloS …, 2017 - mayoclinic.elsevierpure.com
Background and objective Interstitial lung disease (ILD) remains the number one cause of
mortality in scleroderma (SSc). Our goal was to determine the effectiveness of …
mortality in scleroderma (SSc). Our goal was to determine the effectiveness of …
Mycophenolate mofetil for scleroderma-related interstitial lung disease: A real world experience
M Baqir, A Makol, TG Osborn, BJ Bartholmai… - PLOS …, 2017 - econpapers.repec.org
Background and objective: Interstitial lung disease (ILD) remains the number one cause of
mortality in scleroderma (SSc). Our goal was to determine the effectiveness of …
mortality in scleroderma (SSc). Our goal was to determine the effectiveness of …